Sanctuary Advisors LLC bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 18,901 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,453,000.
Other large investors have also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the first quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after acquiring an additional 423 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of ANI Pharmaceuticals during the first quarter valued at $2,706,000. Finally, Norges Bank purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $625,000. Institutional investors and hedge funds own 76.05% of the company’s stock.
Analyst Ratings Changes
ANIP has been the subject of several analyst reports. Guggenheim reissued a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Finally, Canaccord Genuity Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $105.00.
ANI Pharmaceuticals Price Performance
ANIP opened at $78.53 on Friday. The company’s 50 day simple moving average is $81.26 and its 200 day simple moving average is $79.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 1 year low of $62.60 and a 1 year high of $99.50. The stock has a market capitalization of $1.79 billion, a PE ratio of 19.88 and a beta of 0.43.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.
Insider Buying and Selling at ANI Pharmaceuticals
In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total value of $284,918.00. Following the sale, the chief financial officer owned 177,543 shares of the company’s stock, valued at $15,268,698. This represents a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 85,179 shares of company stock worth $6,722,596. 8.10% of the stock is currently owned by company insiders.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
